Eliminate termination of chemical dependency voucher program
Summary
SB 135 would repeal Section 7 of Chapter 187, Laws of 2023, thereby removing the scheduled termination of Montana’s chemical dependency treatment voucher program. In practical terms, the bill preserves the voucher program rather than allowing it to sunset under prior law. The measure is very short and contains no new program design, eligibility, funding, or administrative changes beyond eliminating the termination provision and making that repeal effective immediately upon passage and approval.
Because the bill simply deletes the sunset language, it would affect the existing statutory framework for chemical dependency treatment vouchers by keeping the program in place. It does not create a new entitlement or expand benefits on its face, but it would continue the state’s authority to operate the voucher program for substance use disorder treatment. The bill’s legal effect is limited to repealing the 2023 termination clause and preventing the program from ending on the previously scheduled date.
Impact
The bill would amend Montana law by repealing Section 7 of Chapter 187, Laws of 2023, which had set the chemical dependency treatment voucher program to terminate. This would preserve the program in state law and avoid its automatic expiration. The affected parties are the state agencies administering the voucher program, treatment providers that accept vouchers, and individuals seeking chemical dependency or substance use disorder treatment through the program.
Sentiment
The available voting history suggests the bill was not controversial at the committee stage, as it received an 11-0 vote to table in the Senate Public Health, Welfare and Safety Committee. There are no committee transcripts provided, so there is little direct evidence of debate or opposition in the record supplied. Overall, the bill appears to have been treated as a narrow policy measure focused on maintaining an existing treatment resource.
Contention
The main point of contention, to the extent one existed, would have been whether the chemical dependency treatment voucher program should continue beyond its scheduled termination. Supporters would favor preserving access to treatment for people with substance use disorders, while any opponents might have questioned the program’s cost, effectiveness, or whether it should remain temporary. However, the provided record does not show active floor debate or recorded opposition, and the unanimous committee vote indicates limited visible conflict in committee.